BCRX Q4 2023 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$93M+17.4% YoY

Gross Profit

$92M98.2% margin

Operating Income

-$43M-45.7% margin

Net Income

-$62M-66.1% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+7.7%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$517M

Total Liabilities

$972M

Stockholders' Equity

-$456M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$93M	$80M	+17.4%
Gross Profit	$92M	$77M	+19.1%
Operating Income	-$43M	-$46M	+7.9%
Net Income	-$62M	-$72M	+13.7%

Revenue Segments

Product

$239M100%